Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling. Diphyllin has anti-inflammatory activities, it shows 50% inhibition of NO production from peritoneal macrophages. Diphyllin also has in vitro antileishmanial activity, it exerts a strong specific inhibitory activity (IC50 = 0.2 microM) resulting from the inhibition of parasite internalization within macrophages.